Linked e-resources
Details
Table of Contents
Chapter 1 Introduction: Motivations for Next-Generation ADCs
Chapter 2 Combining ADCs with Immuno-oncology Agents
Chapter 3 Improving the Safety Profile of ADCs
Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development
Chapter 5 Regulatory Considerations and Companion Diagnostics
Chapter 6 ADC Process Development and Manufacturing
Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development
Chapter 8 Next generation payloads for ADCs
Chapter 9 Delivering more payload: High DAR ADCs
Chapter 10 Site-Specific Antibody Drug Conjugates
Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates
Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates
Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment
Chapter 14 Next Horizons: ADCs Beyond Oncology.
Chapter 2 Combining ADCs with Immuno-oncology Agents
Chapter 3 Improving the Safety Profile of ADCs
Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development
Chapter 5 Regulatory Considerations and Companion Diagnostics
Chapter 6 ADC Process Development and Manufacturing
Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development
Chapter 8 Next generation payloads for ADCs
Chapter 9 Delivering more payload: High DAR ADCs
Chapter 10 Site-Specific Antibody Drug Conjugates
Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates
Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates
Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment
Chapter 14 Next Horizons: ADCs Beyond Oncology.